 |
BioWorld-International-2006-09-13
Intercell's Stock Climbs On $77M Wyeth Adjuvant Deal
Intercell's Stock Climbs On $77M Wyeth Adjuvant Deal
Shares in Intercell AG rose to an all-time high Tuesday during trading on the Vienna Stock Exchange on news that the company licensed its IC31 vaccine adjuvant to Wyeth, in a nonexclusive deal worth up to $77 million in up-front, option and milestone payments. Intercell would also gain royalties on product sales. (BioWorld International)